ATE490975T1 - 4-METHYLHEXANOIC KAHALALIDE F COMPOUND - Google Patents

4-METHYLHEXANOIC KAHALALIDE F COMPOUND

Info

Publication number
ATE490975T1
ATE490975T1 AT03779140T AT03779140T ATE490975T1 AT E490975 T1 ATE490975 T1 AT E490975T1 AT 03779140 T AT03779140 T AT 03779140T AT 03779140 T AT03779140 T AT 03779140T AT E490975 T1 ATE490975 T1 AT E490975T1
Authority
AT
Austria
Prior art keywords
kahalalide
methylhexanoic
compound
antitumoral
antiviral
Prior art date
Application number
AT03779140T
Other languages
German (de)
Inventor
Glynn Faircloth
Mariano Elices
Halina Sasak
Marin Pablo Aviles
Marchante Maria Del Carmen Cuevas
Original Assignee
Pharma Mar Sau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2002/004735 external-priority patent/WO2003033012A1/en
Priority claimed from GBGB0304367.6A external-priority patent/GB0304367D0/en
Priority claimed from GB0314725A external-priority patent/GB0314725D0/en
Application filed by Pharma Mar Sau filed Critical Pharma Mar Sau
Priority claimed from PCT/US2003/033207 external-priority patent/WO2004035613A2/en
Application granted granted Critical
Publication of ATE490975T1 publication Critical patent/ATE490975T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The present invention is directed to new kahalalide antitumoral compounds, in particular to analogues of kahalalide F, useful as antitumoral, antiviral, antifungal agents and in the treatment of psoriasis.
AT03779140T 2002-10-18 2003-10-20 4-METHYLHEXANOIC KAHALALIDE F COMPOUND ATE490975T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/GB2002/004735 WO2003033012A1 (en) 2001-10-19 2002-10-18 Kahalalide compounds for use in cancer therapy
GBGB0304367.6A GB0304367D0 (en) 2003-02-26 2003-02-26 Methods for treating psoriasis
GB0314725A GB0314725D0 (en) 2003-06-24 2003-06-24 New antitumoral compounds
PCT/US2003/033207 WO2004035613A2 (en) 2002-10-18 2003-10-20 4-methylhexanoic kahalaide f compound

Publications (1)

Publication Number Publication Date
ATE490975T1 true ATE490975T1 (en) 2010-12-15

Family

ID=35276268

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03779140T ATE490975T1 (en) 2002-10-18 2003-10-20 4-METHYLHEXANOIC KAHALALIDE F COMPOUND

Country Status (12)

Country Link
KR (2) KR20110114690A (en)
AT (1) ATE490975T1 (en)
AU (1) AU2003285911B2 (en)
CY (1) CY1111319T1 (en)
DE (1) DE60335292D1 (en)
DK (1) DK1572726T3 (en)
HK (1) HK1082261A1 (en)
IL (1) IL167724A (en)
NO (1) NO333448B1 (en)
PL (1) PL209129B1 (en)
PT (1) PT1572726E (en)
SI (1) SI1572726T1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0321066D0 (en) * 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
GB0408958D0 (en) * 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9302046D0 (en) * 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
AU1074902A (en) * 2000-10-31 2002-05-15 Pharma Mar Sa Kahalalide f
AU2002334203C1 (en) * 2001-10-19 2008-10-09 Pharma Mar, S.A. Kahalalide compounds for use in cancer therapy

Also Published As

Publication number Publication date
NO333448B1 (en) 2013-06-10
CY1111319T1 (en) 2015-08-05
HK1082261A1 (en) 2006-06-02
AU2003285911B2 (en) 2009-11-19
AU2003285911A1 (en) 2004-05-04
NO20052379L (en) 2005-07-15
PT1572726E (en) 2011-02-14
DE60335292D1 (en) 2011-01-20
KR101149095B1 (en) 2012-05-30
SI1572726T1 (en) 2011-04-29
NO20052379D0 (en) 2005-05-13
KR20110114690A (en) 2011-10-19
PL377056A1 (en) 2006-01-23
KR20050070056A (en) 2005-07-05
DK1572726T3 (en) 2011-03-28
IL167724A (en) 2012-01-31
PL209129B1 (en) 2011-07-29

Similar Documents

Publication Publication Date Title
CY1112743T1 (en) STEERIFIOMETRICULARLY enriched 3-Aminocarbonyl bicyclic pyrimidinodiamine compounds and their uses
DK1663242T3 (en) 2,4-Pyrimidinediamine compounds and use as antiproliferative agents
EA200400971A1 (en) Fluorine-substituted cycloalkanoylindoles, compositions containing such compounds, and methods of treatment
BRPI0418251A (en) phosphonates, monophosphonamidates, bisphosphonamidates for the treatment of viral diseases
EA200500392A1 (en) PYRIMIDINE DERIVATIVES AND THEIR APPLICATION AS CB2 MODULATORS
BG66084B1 (en) Cyclopentanoindoles, compositions containing such compounds and their use
BR0211390A (en) Treatment of nail infections with at
EA200401157A1 (en) N-AMINOACETYLPYRROLIDIN-2-CARBONITRYLES AND THEIR APPLICATION AS DDP-IV Inhibitors
EA200602221A1 (en) NEW APPLICATION OF PEPTIDE CONNECTIONS FOR THE TREATMENT OF PAIN IN TRIGEMINAL NEURALGIA
BG66080B1 (en) Substituted thioacetamides
MXPA04003796A (en) Substituted thioacetamides.
ATE510822T1 (en) POTASSIUM CHANNEL INHIBITORS
ATE486915T1 (en) AZEOTROP-LIKE COMPOSITION OF 1,2-DICHLORO-3,3,3-TRIFLUOROPROPENE AND HYDROGEN FLUORIDE
ATE549024T1 (en) QUINAZOLINE POTASSIUM CHANNEL INHIBITORS
DE60306934D1 (en) Use of nitrile compounds as a medicament
MXPA05004133A (en) 4-methylhexanoic kahalaide f compound.
MXPA02011039A (en) Fungicidal combinations of active agents.
DE602004028493D1 (en) Isoquinolinone POTASSIUM CHANNEL INHIBITORS
BR0115139A (en) Bisheterocyclic compounds with antitumor and chemosensitizing activity
ATE372330T1 (en) N-SULFONYLUREA APOPTOSIS PROMOTER
CY1111319T1 (en) 4-Methyl-hexanoic acid compound F
BR0312183A (en) Use of benziselenazolone compounds against ischemic myocardial injury
ES2194744T3 (en) DERIVATIVES OF QUINOCARDINE, ITS PREPARATION PROCEDURE AND ITS APPLICATION AS ANTIFUNGICOS.
MX2008001548A (en) Antitumoral compounds.
TW200607493A (en) Potassium channel inhibitors

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1572726

Country of ref document: EP